Elevation Oncology, Inc. Banner Image

Elevation Oncology, Inc.

  • Ticker ELEV
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Elevation Oncology, Inc. Logo Image
  • 11-50 Employees
  • Based in New York City, New York
Elevation Oncology is an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. They are rethinking drug development by seeking out innovative, selective cancer therapies that can be matched to a patient's unique tumor characteristics. Their lead candidateMore, EO-3021, is a potential best-in-class antibody drug conjugate (ADC) designed to target Claudin 18.2, a clinically validated molecular target. EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology is evaluating EO-3021 in a Phase 1 study in patients with advanced, unresectable or metastatic solid tumors likely to express Claudin 18.2 including gastric, gastroesophageal, pancreatic or esophageal cancers. They are also exploring other opportunities through new or existing partnerships and business development opportunities to expand its novel oncology pipeline.
Elevation Oncology, Inc.

Most Recent Annual Report

Elevation Oncology, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Elevation Oncology, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!